Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sangamo Biosciences Inc Raises FY 2012 Revenue Guidance


Wednesday, 24 Oct 2012 04:02pm EDT 

Sangamo Biosciences Inc announced that for fiscal 2012, it expects revenues to be in the range of $18 to $20 million, inclusive of research funding from Shire (earlier guidance was $14 to $18 million). According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $17.63 million for fiscal 2012. 

Company Quote

13.08
0.75 +6.08%
4:00pm EDT